key: cord-0307541-3k7z8ur8 authors: Urlaub, E.; Hayer, J. title: Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in samples from vaccinated individuals date: 2021-12-21 journal: nan DOI: 10.1101/2021.12.17.21267927 sha: 3cefde840d4acebb6244ff1fe99ca65599cf29ed doc_id: 307541 cord_uid: 3k7z8ur8 Objective The study aimed to establish the performance of the SARS-CoV-2 Rapid Antibody Test (IgG and IgM) and the Elecsys(R) Anti-SARS-CoV-2 S assay in vaccinated individuals. Methods A panel of serum samples from Boca Biolistics was utilized to assess antibodies following vaccination, consisting of samples drawn prior to vaccination, after the first dose, or at least 14 days after the second dose of Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2 COVID-19 vaccines. Agreement between the two methods was measured and stratified by test evaluator and assay lot. Results Agreement between the SARS-CoV-2 Rapid Antibody Test (IgG) and Elecsys Anti-SARS-CoV-2 S assay qualitative measurements at the different assessment points for both mRNA-1273 and BNT162b2 ranged between 97.06% (95% confidence interval [CI] 84.67, 99.93) to 100% (95% CI 82.35, 100). Agreement of the SARS-CoV-2 Rapid Antibody Test (IgG) with the Elecsys Anti-SARS-CoV-2 S assay was not highly influenced by either lot or evaluator. There was a medium-to-strong correlation between the semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG) result and quantitative Elecsys Anti-SARS-CoV-2 S assay in samples taken after both doses of the vaccines, with higher intensity bands being associated with higher total anti-S antibody titer (mRNA-1273, p=0.0019; BNT162b2, p<0.0001). Conclusion Semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys Anti-SARS-CoV-2 S assay correlated well, suggesting that the SARS-CoV-2 Rapid Antibody Test (IgG) is helpful in understanding the immune response post-vaccination. The current data support the use of the SARS-CoV-2 Rapid Antibody Test (IgG) in the vaccinated population. individuals. 18 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 2 A panel of serum samples from Boca Biolistics was utilized to assess antibodies 20 following vaccination, consisting of samples drawn prior to vaccination, after the first 21 dose, or at least 14 days after the second dose of Moderna mRNA-1273 or Pfizer-22 BioNTech BNT162b2 COVID-19 vaccines. Agreement between the two methods 23 was measured and stratified by test evaluator and assay lot. 24 Agreement between the SARS-CoV-2 Rapid Antibody Test (IgG) and Elecsys Anti-26 SARS-CoV-2 S assay qualitative measurements at the different assessment points 27 for both mRNA-1273 and BNT162b2 ranged between 97.06% (95% confidence 28 interval [CI] 84.67, 99.93) to 100% (95% CI 82.35, 100) . Agreement of the SARS- 29 CoV-2 Rapid Antibody Test (IgG) with the Elecsys Anti-SARS-CoV-2 S assay was 30 not highly influenced by either lot or evaluator. There was a medium-to-strong 31 correlation between the semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG) 32 result and quantitative Elecsys Anti-SARS-CoV-2 S assay in samples taken after 33 both doses of the vaccines, with higher intensity bands being associated with higher 34 total anti-S antibody titer (mRNA-1273, p=0.0019; BNT162b2, p<0.0001). 35 Conclusion 36 Semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 21, 2021. Serologic immunoassays are vital in the global management of the COVID-19 63 pandemic. Measurement of antibodies to SARS-CoV-2 is important for improving 64 disease management, and accurate tests, with validated sensitivity and specificity, 65 are essential for obtaining reliable results when monitoring the pandemic (1). 66 Serologic assays can provide evidence of recent or past infection (2) , and identify 67 those individuals still at risk of infection (3). 68 Infection with SARS-CoV-2 elicits a strong neutralizing antibody response (4), and 69 antibodies that bind via the spike protein act as neutralizing antibodies (5, 6). Several 70 studies have shown good correlation between anti-S antibodies and functional virus 71 neutralization (7-11). Neutralization assays utilizing live virus require biosafety level 3 72 containment, which can be labor intensive and low throughput (12-14); therefore is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 21, 2021. CoV-2 assay that targets the nucleocapsid protein (27). 103 The objective of this study was to establish the performance of the SARS-CoV-2 104 Rapid Antibody Test and the Elecsys Anti-SARS-CoV-2 S assay in serum samples 105 obtained from individuals who had received a COVID-19 vaccination. Study design 108 The study was a retrospective performance study conducted at Roche Diagnostics 109 GmbH (Mannheim, Germany). All samples were analyzed with the SARS-CoV-2 110 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10. 1101 Rapid Antibody Test and compared with the Elecsys Anti-SARS-CoV-2 S assay. 111 Tests were conducted as per manufacturer's instructions (23). Table 119 1). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Test. The readout was visually assessed at 10 minutes by two different independent 137 evaluators; these evaluators were not the operators who had performed the test. In 138 accordance with manufacturer's instructions, the sample was considered positive if 139 the control line and at least one colored band/test line at G or M became apparent 140 (qualitative determination). As an exploratory analysis, results were further defined 141 by the intensity of the band to provide semi-quantitative data (Supplemental Table 142 2). Data are presented separated by lot and by evaluator. In the event of an invalid 143 result, the test would be repeated. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Anti-SARS-CoV-2 S assay per vaccine type were calculated per lot. Two-sided 95% 160 Clopper-Pearson confidence intervals (CI) for the agreement rates are given. 161 Correlation between the semi-quantitative SARS-CoV-2 Rapid Antibody Test data 162 and quantitative Elecsys Anti-SARS-CoV-2 S assay data was assessed using the (Table 1) . No invalid results were generated using either test. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 191 There was poor agreement between the SARS-CoV-2 Rapid Antibody Test (IgM) 192 and Elecsys Anti-SARS-CoV-2 S assay qualitative measurements at the different 193 assessment points for both BNT162b2 and mRNA-1273 ranging from 14.71% (95% 194 CI 4.95, 31.06) to 83.33% (95% CI 35.88, 99.58) with many false-negatives (Table 195 2). 196 Using the in-house negative panel, there were no false-positive results for either lot 197 or evaluator (Supplemental Table 3 ). Elecsys Anti-SARS-CoV-2 S assay (quantitative) 200 There was a medium-to-strong correlation between the semi-quantitative SARS- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Table 4 ). There was no correlation between the 206 quantitative Elecsys Anti-SARS-CoV-2 S assay result and the intensity of the SARS-207 CoV-2 Rapid Antibody Test (IgM) (Supplemental Table 4 ). 208 Agreement between the semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgM) 209 and quantitative Elecsys Anti-SARS-CoV-2 S assay was poor, with many samples is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 21, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 or BNT162b2 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Tables and figures for ms 515 Serology assays to manage COVID-19 Multicentre performance evaluation of the Elecsys Anti-SARS-CoV-2 345 immunoassay as an aid in determining previous exposure to SARS-CoV-2 Dis Ther The power of antibody-based surveillance Neutralizing antibody titres in SARS-CoV-2 infections Molecular interaction and inhibition 354 of SARS-CoV-2 binding to the ACE2 receptor Structural basis for the 356 recognition of SARS-CoV-2 by full-length human ACE2 Evaluation of high-throughput SARS-CoV-2 361 17 serological assays in a longitudinal cohort of patients with mild COVID-19: clinical 362 sensitivity, specificity, and association with virus neutralization test Clinical and analytical performance of an automated serological test that 367 identifies S1/S2-neutralizing IgG in COVID-19 patients semiquantitatively Longitudinal serological analysis and neutralizing 372 antibody levels in coronavirus disease 2019 convalescent patients SARS-CoV-2 antibodies with eight commercially available immunoassays SARS-CoV-2 protection correlate: Head-to-head comparison of two quantitative 381 S1 assays in pre-characterized oligo-/asymptomatic patients Establishment and 385 validation of a pseudovirus neutralization assay for SARS-CoV-2 Quantifying 392 absolute neutralization titers against SARS-CoV-2 by standardized virus 393 neutralization assay allows for cross-cohort comparisons of COVID-19 sera Development of a rapid focus reduction neutralization test assay for 398 measuring SARS-CoV-2 neutralizing antibodies Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 401 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial Deployment of SARS-CoV-2 405 19 diagnostic testing: challenges and key considerations for the future Fact sheet for healthcare providers administering 408 vaccine (vaccination providers): emergency use authorization (EUA) of the 409 COVID-19 vaccine to prevent coronavirus disease Fact sheet for healthcare providers administering vaccine 413 (vaccination providers): emergency use authorization (EUA) of the moderna 414 COVID-19 vaccine to Durability 421 of responses after SARS-CoV-2 mRNA-1273 vaccination SARS-CoV-2 vaccination 426 in rituximab-treated patients: B cells promote humoral immune responses in the 427 presence of T-cell-mediated immunity Usefulness of IVD kits for 430 the assessment of SARS-CoV-2 antibodies to evaluate the humoral response to 431 vaccination Anti-SARS-CoV-2 receptor-binding domain total 434 antibodies response in seropositive and seronegative healthcare workers 435 undergoing COVID-19 mRNA BNT162b2 Vaccination Performance evaluation of the Roche Elecsys 440 Anti-SARS-CoV-2 S immunoassay Performance 442 of the rapid high-throughput automated electrochemiluminescence immunoassay 443 targeting total antibodies to the SARS-CoV-2 spike protein receptor binding 444 domain in comparison to the neutralization assay SARS-CoV-2 Rapid Antibody Test Clinical performance evaluation of a SARS-CoV-2 Rapid 449 21 Antibody Test for determining past exposure to SARS-CoV-2 Neutralizing antibody levels are 453 highly predictive of immune protection from symptomatic SARS-CoV-2 infection Infliximab is 459 associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-460 19 SARS-CoV-2 vaccines in patients with IBD Antibody response to SARS-CoV-2 vaccination is extremely vivacious in 463 subjects with previous SARS-CoV-2 infection Vaccination strategy and anti -SARS-CoV-466 S titers in healthcare workers of the INT -IRCCS "Fondazione Pascale Infect Agent Cancer BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic 471 leukemia Antibody 474 response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated 475 diseases: a controlled study among hospital workers and elderly A comparative evaluation between 479 the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™ 480 SARS CoV-2 IgG assay High seroprevalence 485 of anti-SARS-CoV-2 antibodies in Chelsea Point-of-care serological assays for delayed SARS-CoV-490 2 case identification among health-care workers in the UK: A prospective 491 multicentre cohort study Valuable Epidemiological Tools in Challenging Settings. Microbiol 495 Spectr SARS-CoV-2 antibody response following vaccination with BNT162b2 and 498 mRNA-1273 Evaluation of three anti CoV-2 serologic immunoassays for post-vaccine response Kinetics of anti-SARS-CoV-2 antibody 506 responses 3 months post complete vaccination with BNT162b2; A prospective 507 study in 283 health workers Hypertension prevalence 512 among adults aged 18 and over: United States is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 21, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 21, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021